Shanghai Kunya Medical Equipment has garnered 100 million yuan ($15 million) in its Series C round of financing led by Haier Biomedical, while Xbiome has secured ‘tens of millions of US dollars’ in its Series B+ round of financing co-led by Primavera Capital Group and Gaorong Capital.
Kunya Medical nets $15m in Series C round
Medical equipment service provider Shanghai Kunya Medical Equipment Co., Ltd said on Friday that it has raised 100 million yuan ($15 million) in its Series C round led by Haier Biomedical, a healthcare based subsidiary of Chinese global home appliance giant Haier Group Corporation.
The round was joined by new investor Dongfang Jiafu Investment, the arm of Shanghai-listed Zhejiang Orient Financial Holdings Group. Returning backer Legend Capital also participated in the funding round, according to a company statement on Friday.
Boutique investment bank Haoyue Capital facilitated the transaction.
Founded in 2009, Kunya has been engaged in the medical equipment maintenance business. Kunya has also rolled out a digital medical platform to provide cloud-computing and big data-focused medical management. The company claims to have served over 600 hospitals.
Kunya earlier raised 37.50 million yuan ($5.7 million) from Legend Capital and others in 2018. Prior to that in the same year, Legend and Highlight Capital had together invested a similar amount for Kunya’s Series B round.
Legend Capital backs Xbiome
AI-based microbiome drug-maker Xbiome Co., Ltd has secured ‘tens of millions of US dollars’ in its Series B+ round co-led by China-based global investment firm Primavera Capital Group and returning backer Gaorong Capital, per a company statement on Friday.
Existing investors 5Y Capital (formerly Morningside Venture Capital) and Legend Capital also re-upped in the round. Biotechnology-focused Yayi Capital and Yimei Capital are the new investors in the round.
Xbiome will deploy the proceeds for clinical trials and developing new pipelines.
Headquartered in Shenzhen, Xbiome leverages AI technology and approaches to develop innovative gut microbiome drugs.
The three-year-old company is also backed by Alwin Capital, ZhenFund, Zhuhai Lihe Hongxin Investment Management, among others.